Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a panel discussion at the BMO Biopharma Spotlight Series: Latest Advances in Genome / Epigenome Editing virtual event. The panel, titled “Latest Advances in Epigenetic Editing,” will be held Tuesday September 26, 2023 at 1:00 p.m. ET.
The event will be made available live only to clients of BMO. Institutional investors interested in meeting with management during the conference may reach out to their BMO representative.
About Epic Bo
Investor Contact Shawn M. Cox Epic Bio Manager, Investor Relations, Corporate Communications [email protected] Media Contact Lisa Raffensperger Ten Bridge Communications [email protected] (617) 903-8783
Future of Work Expo #TECHSUPERSHOW Expo Hall Open
MSPs and Compliance: Building a Security and Compliance Framework